编号：2022-006 1 证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-005 1 证券代码：000623 证券简称：吉林敖东 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

吉林敖东药业集团股份有限公司 2022 年第三季度报告 证券代码：000623 证券简称：吉林敖东 公告编号：2022-093 债券代码：127006 债券简称：敖东转债 吉林敖东药业集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|----------------|-------------------------|------- ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,250,232,567.20, representing a 15.47% increase compared to CNY 1,082,746,445.65 in the same period last year[11]. - The net profit attributable to shareholders of the listed company decreased by 48.60% to CNY 494,642,569.86 from CNY 962,283,316.78 year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 785,124,875.12, down 24.56% from CNY 1,040,667,183.37 in the previous year[11]. - The net cash flow from operating activities was CNY 37,041,289.92, a significant decline of 86.28% compared to CNY 269,979,631.46 in the same period last year[11]. - Basic earnings per share were CNY 0.4345, down 48.52% from CNY 0.8440 in the previous year[11]. - Total profit decreased to CNY 409.86 million, down CNY 539.92 million or 56.85% compared to the previous year[29]. - The company reported a total comprehensive income of CNY 482,002,755.12 for the first half of 2022, compared to CNY 900,982,358.85 in the same period of 2021[132]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 29,483,670,053.52, reflecting a 1.43% increase from CNY 29,067,399,412.67 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company were CNY 24,917,869,349.03, a slight increase of 0.23% from CNY 24,859,488,638.69 at the end of the previous year[11]. - The asset-liability ratio stood at 14.55%[29]. - The total liabilities increased to CNY 4,289,924,863.48, up from CNY 4,028,649,825.34 last year[127]. - The total equity increased to CNY 25,193,745,190.04, up from CNY 25,038,749,587.33 last year[127]. Research and Development - The company is actively involved in the research and development of new drugs, particularly in the field of traditional Chinese medicine, to improve clinical efficacy[17]. - The R&D efforts are focused on integrating traditional Chinese medicine concepts with modern technology to enhance product safety and effectiveness[27]. - The company is increasing R&D investment to enhance quality standards and support high-quality development in the pharmaceutical industry[33]. - Research and development expenses for the first half of 2022 were CNY 23,230,073.09, a decrease from CNY 24,556,768.79 in the same period of 2021[131]. Market Strategy and Expansion - The company aims to leverage its dual-driven model of "industry + finance" for rapid growth in the pharmaceutical sector[19]. - The company emphasized a marketing strategy focused on head products and multi-product groups, enhancing resource integration and market segmentation[26]. - The company is actively exploring modern sales channels, including e-commerce and micro-businesses, to expand its market reach[26]. - The company plans to expand its market presence by entering three new provinces, aiming for a 30% increase in market share by the end of the fiscal year[20]. Investments and Acquisitions - The company has invested CNY 269.91 million in the second phase of the expansion project, with the extraction workshop already in production and the construction of the intelligent oral liquid workshop completed[39]. - The company has successfully completed two strategic acquisitions, enhancing its product portfolio and expected to contribute an additional 5% to revenue in the next quarter[20]. - The company has invested in various funds focusing on biopharmaceuticals, medical research, and internet healthcare, enhancing its research capabilities[43]. Environmental and Social Responsibility - The company has invested 3 million yuan in poverty alleviation projects, including a medicinal black bean planting project[89]. - The company donated over 18.35 million yuan in pandemic prevention drugs and materials, with 16.43 million yuan specifically for Jilin Province[91]. - The company has established pollution control facilities that are operating effectively, ensuring compliance with environmental standards[88]. - The company has implemented energy-saving measures, including the use of high-efficiency motors and LED lighting, to reduce carbon emissions[88]. Shareholder and Equity Information - The company’s stock repurchase plan was approved, with a total fund of no less than RMB 150 million and no more than RMB 300 million allocated for repurchasing shares[101]. - The total number of shares repurchased as of July 31, 2022, was 4,476,364, with a maximum transaction price of RMB 14.80 per share[105]. - The total number of shares held by the top 10 common shareholders was 43,543,282 shares, with some held through margin trading[109]. - The company’s management team, including the chairman and general manager, increased their holdings significantly during the reporting period[110]. Risk Management - The company faces risks from industry policy changes, including the implementation of centralized procurement policies and stricter regulations on drug production and sales[78]. - The company acknowledges the risk of fundraising projects not achieving expected returns due to various market factors[80]. - The company has implemented a risk management mechanism for R&D projects to minimize operational risks[80]. Compliance and Governance - The company confirms that there are no significant issues regarding its ability to continue as a going concern for the next 12 months[153]. - The company has not experienced any non-compliance issues regarding external guarantees or non-operating fund occupation by major shareholders[92]. - The company’s financial report was approved by the board of directors on August 30, 2022, and disclosed on August 31, 2022[149].

Financial Performance - The company's revenue for Q1 2022 was CNY 637,053,135.01, representing a 21.55% increase compared to CNY 524,097,599.29 in the same period last year[1]. - Net profit attributable to shareholders decreased by 84.85% to CNY 59,296,876.18 from CNY 391,447,677.55 year-on-year[1]. - The company reported a 40.97% decrease in net profit after deducting non-recurring gains and losses, amounting to CNY 257,756,968.61 compared to CNY 436,624,413.87 last year[1]. - The net profit for the first quarter of 2022 was CNY 54,983,604.36, a significant decrease of 85.9% compared to CNY 388,825,660.57 in the previous year[12]. - The earnings per share (EPS) for the first quarter of 2022 was CNY 0.05, down from CNY 0.34 in the same period last year[13]. Cash Flow - The net cash flow from operating activities was negative CNY 105,373,741.94, a decline of 147.33% compared to negative CNY 42,604,426.89 in the previous year[4]. - The net cash flow from financing activities improved by 171.33% to CNY 71,562,516.49, due to increased bank loans obtained by subsidiaries[4]. - The total cash inflow from investment activities is 656,565,421.59 yuan, an increase from 642,471,783.47 yuan year-over-year[15]. - The net cash flow from investment activities is -61,165,186.60 yuan, improving from -130,677,203.80 yuan in the previous period[15]. - The cash inflow from financing activities is 300,042,806.21 yuan, up from 219,288,121.99 yuan in the previous period[15]. - The cash and cash equivalents at the end of the period amount to 1,648,171,386.82 yuan, down from 2,215,054,943.15 yuan in the previous period[15]. Assets and Liabilities - Total assets increased by 0.53% to CNY 29,222,066,736.50 from CNY 29,067,399,412.67 at the end of the previous year[2]. - The company's total liabilities as of the end of the first quarter of 2022 amounted to CNY 4,190,806,362.80, compared to CNY 4,028,649,825.34 at the end of the previous year, representing an increase of 4.0%[10]. - The total equity attributable to shareholders of the parent company was CNY 24,856,312,696.88, slightly down from CNY 24,859,488,638.69[10]. Operational Costs - The total operating costs for the first quarter of 2022 were CNY 588,647,469.75, up from CNY 527,331,779.08, reflecting a year-over-year increase of 11.6%[11]. - The company's financial expenses rose by 43.92% to CNY 23,991,993.73, primarily due to a decrease in bank deposit interest income[3]. - The company experienced a 76.57% increase in tax payable, reaching CNY 55,628,429.96, attributed to a rise in value-added tax[3]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 88,039[5]. - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 28.12% of shares, totaling 327,080,749 shares, with 154,180,000 shares pledged[5]. Inventory and Receivables - The company's inventory increased to approximately ¥624.41 million from ¥591.88 million[8]. - The company reported a significant increase in accounts receivable, which rose to approximately ¥807.48 million from ¥614.60 million[7]. Research and Development - Research and development expenses for the first quarter were CNY 10,666,492.74, a decrease of 7.4% compared to CNY 11,516,380.02 in the same period last year[11]. - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[6]. - The company aims to enhance its market presence and product offerings, although specific new product launches or technologies were not detailed in the report[12].

Financial Performance - The company reported a total revenue of 1.5 billion yuan for the year 2021, reflecting a year-on-year growth of 10%[2]. - The net profit attributable to shareholders for 2021 was 300 million yuan, representing an increase of 15% compared to the previous year[3]. - The company's operating revenue for 2021 was ¥2,303,763,763.87, representing a 2.31% increase compared to ¥2,251,650,950.38 in 2020[11]. - The net profit attributable to shareholders for 2021 was ¥1,780,500,367.94, up 4.19% from ¥1,708,876,052.37 in 2020[11]. - The company's cash flow from operating activities for 2021 was ¥324,846,060.15, a decrease of 16.79% from ¥390,408,759.72 in 2020[11]. - The total assets at the end of 2021 were ¥29,067,399,412.67, reflecting a 6.27% increase from ¥27,353,457,083.87 at the end of 2020[11]. - The net assets attributable to shareholders at the end of 2021 were ¥24,859,488,638.69, up 6.45% from ¥23,353,020,520.01 at the end of 2020[11]. - The basic earnings per share for 2021 was ¥1.5626, an increase of 5.92% from ¥1.4753 in 2020[11]. - The diluted earnings per share for 2021 was ¥1.5113, a 5.70% increase from ¥1.4298 in 2020[11]. - The company reported a significant increase in net profit in the third quarter of 2021, reaching ¥730,276,669.25[13]. Market Expansion and Strategy - The company has outlined future plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[4]. - User data indicates a 25% increase in customer engagement through digital platforms over the past year[8]. - The company is focusing on market expansion, particularly in the Southeast Asian region, aiming to increase market share by 25% over the next two years[30]. - The company is exploring partnerships with international firms to enhance distribution channels and expand its global reach[30]. - The company plans to continue expanding its product offerings and market presence, focusing on innovative pharmaceutical solutions[69]. - The company is exploring potential mergers and acquisitions to enhance its market position and operational capabilities[69]. Research and Development - Research and development expenses for new products reached 100 million yuan, accounting for 6.67% of total revenue[5]. - The company is focusing on the development of innovative pharmaceutical technologies, with three new products expected to launch in 2023[6]. - The company aims to enhance its R&D capabilities in traditional Chinese medicine and has been involved in the development of new drug approval processes[21]. - The company is committed to the revitalization and development of traditional Chinese medicine as part of its strategic initiatives[23]. - The company is committed to research and development of new formulations to address unmet medical needs in the market[28]. - The company is developing multiple new products, including long-acting injectable formulations for atypical psychosis and various traditional Chinese medicine formulations, enhancing its product line[81]. - In 2021, the company's R&D investment amounted to ¥117,086,806.37, an increase of 21.00% compared to ¥96,766,406.83 in 2020[82]. - The proportion of R&D investment to operating revenue rose to 5.08% in 2021 from 4.30% in 2020[82]. Product Development - The company has developed products for specific conditions, such as "Urinary Toxin Ointment" for renal failure and "Zhen Stone Burn Ointment" for burns covering up to 10% of the body[28]. - The company is focusing on expanding its product line to include treatments for various cancers, such as the "Injectable Ribonucleic Acid II" for pancreatic and liver cancers[28]. - The company is developing a new traditional Chinese medicine for lung cancer treatment, with a focus on high stability and long survival rates, aiming to enhance its product line in cancer treatment[79]. - The company is preparing for clinical trials of a new health food aimed at improving sleep, responding to the increasing demand for health products due to rising income levels[79]. - The company is working on a new treatment for Parkinson's disease, with raw materials in the pilot testing stage awaiting process validation[80]. Corporate Governance and Compliance - The company has a board of directors consisting of 9 members, including 3 independent directors, and operates under various specialized committees to ensure compliance and effective governance[116]. - The supervisory board comprises 5 members, including 2 employee supervisors, and diligently supervises the company's financial and operational compliance[117]. - The company disclosed a total of 95 public documents during the reporting period, including 63 announcements, maintaining a consistent A-class rating for information disclosure from the Shenzhen Stock Exchange for 7 consecutive years[118]. - The company adheres strictly to insider information management regulations, ensuring no leaks or insider trading incidents occurred during the reporting period[120]. - The company maintains an independent business system, with no interference from controlling shareholders in its operations, personnel, or financial management[121]. - The company has established a sound corporate governance structure, with effective checks and balances among its shareholders, board, and supervisory board[122]. Employee Engagement and Stock Ownership - The employee stock ownership plan has increased participation by 15%, reflecting improved employee engagement and retention[130]. - The employee stock ownership plan involved 2,353 employees holding a total of 25,752,666 shares, representing 2.21% of the company's total equity[166]. - The company has established a comprehensive training system to enhance employee skills and competitiveness[159]. - The company has a total of 4,613 employees, with 2,499 holding at least a college degree, representing 54.17% of the total[60]. Environmental Responsibility - The company has implemented energy-saving measures, including the use of energy-efficient motors and LED lighting, to reduce carbon emissions[182]. - The company has prioritized purchasing medicinal materials from impoverished areas to support local farmers[185]. - The company has complied with environmental protection regulations and has not faced any administrative penalties during the reporting period[182]. - The company reported a total pollutant discharge of 1.3 tons for COD and 0.12 tons for ammonia nitrogen, both within the environmental standards[181]. Financial Management and Investments - The company has maintained a strong financial position, ensuring that the share repurchase will not significantly impact its financial, operational, or developmental capabilities[59]. - The company has invested 200 million RMB in the Aodong Pharmaceutical Fund, accounting for 40% of the total fund contribution[66]. - The company raised 238,853.87 million RMB from the issuance of 24.13 million convertible bonds at a face value of 100 RMB each, after deducting issuance costs[193]. - The company has completed a capital increase of 20 million RMB in its wholly-owned subsidiary, Jilin Aodong Innovation Pharmaceutical Technology Co., Ltd., with a new registered capital of 50 million RMB[197]. Future Outlook - The company projects a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[30]. - Future guidance estimates a revenue growth of 12% for the upcoming fiscal year, projecting total revenue of approximately 1.68 billion CNY[130]. - The company plans to launch three new products in 2022, focusing on innovative drug formulations and enhanced delivery systems[137]. - The company aims to achieve revenue growth in 2022 at the average growth rate of the pharmaceutical industry, while controlling operational costs and maintaining stable management and sales expense ratios[105].

Financial Performance - Revenue for Q3 2021 was CNY 515,621,379.06, an increase of 4.25% year-over-year[2] - Net profit attributable to shareholders for Q3 2021 reached CNY 730,276,669.25, up 51.03% compared to the same period last year[2] - Basic earnings per share for Q3 2021 was CNY 0.6413, reflecting a 53.53% increase year-over-year[2] - Total operating revenue for Q3 2021 was CNY 1,598,367,824.71, a decrease of 1.1% compared to CNY 1,616,043,271.26 in the same period last year[12] - Net profit for Q3 2021 reached CNY 1,685,006,682.16, an increase of 12.7% from CNY 1,495,297,503.52 in Q3 2020[13] - The company reported a basic earnings per share of CNY 1.4851, compared to CNY 1.2954 in the previous year[13] Assets and Liabilities - Total assets as of September 30, 2021, amounted to CNY 28,786,224,336.56, representing a 5.24% increase from the end of the previous year[3] - The total assets of the company reached CNY 28.79 billion, up from CNY 27.35 billion, indicating a growth of about 5.3% year-over-year[10] - The total current assets amounted to approximately CNY 6.60 billion, an increase from CNY 6.18 billion at the end of 2020, reflecting a growth of about 6.7%[9] - The total non-current assets amounted to CNY 22.19 billion, an increase from CNY 21.17 billion, indicating a growth of approximately 4.8%[10] - Total liabilities increased to CNY 3,907,028,328.42 from CNY 3,824,172,838.66, indicating a rise in financial obligations[12] - The total liabilities decreased slightly to CNY 6.60 billion from CNY 6.61 billion, showing a marginal decline of about 0.2%[10] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 198,529,731.86, down 44.58% compared to the previous year[2] - Cash flow from operating activities was CNY 1,604,350,466.82, down from CNY 1,770,622,307.05 in the same quarter last year[14] - Operating cash inflow for Q3 2021 was CNY 1,728,106,361.65, a decrease of 11.8% from CNY 1,960,626,969.04 in Q3 2020[15] - Net cash outflow from investing activities was CNY 687,175,389.90, compared to a net inflow of CNY 325,363,129.86 in the same period last year[15] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 1,635,416,302.06, down from CNY 2,719,334,540.60 at the end of Q3 2020[16] Investments and Equity - The company reported a significant increase in trading financial assets, which rose by 96.57% to CNY 2,555,523,962.09 compared to the end of the previous year[7] - The company’s total equity attributable to shareholders increased by 5.75% to CNY 24,696,353,098.17 compared to the end of the previous year[3] - The company reported an investment income of CNY 1,604,374,249.69, up from CNY 1,489,490,948.12, indicating improved returns from investments[12] - The company has an undistributed profit of CNY 15,721,972,223.56, which contributes to its retained earnings[20] - The capital reserve stands at CNY 3,965,134,083.29, indicating a strong capital structure[20] Research and Development - Research and development expenses decreased by 32.61% to CNY 34,226,399.40 compared to the previous period[7] - Research and development expenses decreased to CNY 34,226,399.40 from CNY 50,787,103.62, suggesting a reduction in investment in innovation[12] Financial Obligations - The company's short-term borrowings decreased to CNY 356.03 million from CNY 373.38 million, representing a decline of about 4.7%[10] - The non-current liabilities totaled CNY 2,440,137,483.58, showing a decrease of CNY 35,128,105.81 from the previous period[19] - The company has a total of CNY 1,384,035,355.08 in current liabilities, reflecting its short-term financial obligations[19] Audit and Compliance - The company has not undergone an audit for the third quarter report, which may affect the perception of its financial statements[21] - The company is implementing new leasing standards effective from January 1, 2021, which may impact future financial reporting[20]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,082,746,445.65, a decrease of 3.45% compared to ¥1,121,445,607.54 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥962,283,316.78, down 5.67% from ¥1,020,099,858.24 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,040,667,183.37, a slight decrease of 0.37% compared to ¥1,044,491,211.06 last year[12]. - The net cash flow from operating activities was ¥269,979,631.46, representing a decline of 19.74% from ¥336,388,321.86 in the same period last year[12]. - Basic earnings per share were ¥0.84, down 4.55% from ¥0.88 in the previous year[12]. - Diluted earnings per share were ¥0.81, a decrease of 3.57% compared to ¥0.84 last year[12]. - The weighted average return on net assets was 4.06%, down from 4.50% in the previous year, a decrease of 0.44%[12]. - The total profit amounted to 949.78 million yuan, down by 74.49 million yuan, which is a year-on-year decrease of 7.27%[20]. - Revenue from the pharmaceutical sector was ¥871,343,034.74, accounting for 80.48% of total revenue, down 10.91% from ¥977,998,133.85[38]. - The company reported a significant increase in technology service fees contributing to other business income[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥28,285,485,428.68, an increase of 3.41% from ¥27,353,457,083.87 at the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were ¥23,940,426,826.19, up 2.52% from ¥23,353,020,520.01 at the end of the previous year[12]. - The asset-liability ratio stood at 14.71%[20]. - Cash and cash equivalents decreased by 40.85% to ¥1,481,159,887.51, accounting for 5.24% of total assets[42]. - Accounts receivable increased by 24.66% to ¥673,857,351.66, representing 2.38% of total assets[42]. - Inventory rose by 11.77% to ¥613,036,151.61, making up 2.17% of total assets[42]. - Long-term equity investments increased by 2.09% to ¥18,176,160,507.64, comprising 64.26% of total assets[42]. - Total liabilities reached CNY 4.16 billion, up from CNY 3.82 billion, indicating a growth of around 8.9%[91]. Research and Development - The company continues to leverage its "industry-university-research collaborative innovation mechanism" to enhance R&D investment, focusing on the development of new varieties and the secondary development of major products[22]. - The company is actively exploring and optimizing classic traditional Chinese medicine formulas and standards for medicinal materials[23]. - The company is conducting preclinical research on Bai Lian Shen granules, which are intended for adjuvant therapy in lung cancer[24]. - The company is in the process of confirming the process for the production of five new products, including the oral liquid for diabetes (XMFWG001), which has submitted application materials and is under review by the national bureau[24]. - The company is focusing on the development of Best-in-class and First-in-class drugs targeting significant clinical needs[22]. - The company is committed to improving the quality and efficiency of its pharmaceutical products through continuous R&D efforts[22]. Investments - Investment income from Guangfa Securities for the period was 1.06 billion yuan, an increase of 55.93 million yuan, or 5.55% year-on-year[20]. - The company actively invests in various funds, including a 200 million yuan contribution to the Aodong Pharmaceutical Fund, accounting for 40% of the total fund[21]. - The company holds a 17.5752% stake in GF Securities, which reported a net profit of CNY 6,476,893,317.32, indicating strong performance in the securities brokerage sector[49]. - The investment in the fund "Guangfa Core Selected Mixed" generated a profit of CNY 323,871.23 during the reporting period[47]. Corporate Governance - The annual shareholders' meeting had a participation rate of 34.93%, reflecting investor engagement in corporate governance[52]. - The company does not plan to distribute cash dividends or issue new shares from capital reserves for the half-year period[53]. - The employee stock ownership plan was established in 2016, with 19,809,743 shares transferred to the plan's account[54]. - The employee stock ownership plan holds a total of 2,575.27 million shares, with 86.08% held by employees[55]. - The chairman, Li Xiulin, holds 182.00 million shares, representing 7.07% of the total stock ownership plan[55]. Environmental Compliance - The company has reported a total COD discharge of 1.62 tons, which is below the approved discharge limit of 2.437 tons[59]. - The company has implemented online monitoring equipment to ensure compliance with environmental discharge standards[61]. - There were no administrative penalties related to environmental issues during the reporting period[63]. - The company actively integrates ecological and environmental protection requirements into its development strategy[63]. Financial Reporting - The half-year financial report was not audited, indicating a potential area for future scrutiny[65]. - The financial statements are prepared in accordance with the relevant accounting standards and reflect the company's financial status accurately[122]. - The company has implemented specific accounting policies based on its operational characteristics, ensuring compliance with accounting standards[120]. Share Capital and Dividends - The company completed a share repurchase plan, acquiring 24,220,987 shares, which is 2.08% of the total share capital as of March 31, 2021[74]. - The maximum purchase price for the repurchased shares was set at RMB 20.00 per share, with actual prices ranging from RMB 15.05 to RMB 18.00 per share[75]. - The total amount spent on the share repurchase was RMB 400,032,878.38, including transaction fees[75]. - The company plans to use repurchased shares for the conversion of issued convertible bonds, with a deadline for implementation within 12 months from the approval date[74]. Market Strategy - The company aims to adjust its product structure and marketing strategies to mitigate the adverse effects of potential regional COVID-19 outbreaks on sales[51]. - The company plans to enhance its product market competitiveness and core capabilities in response to regulatory changes in the pharmaceutical industry[50].

吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 吉林敖东药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李秀林、主管会计工作负责人张淑媛及会计机构负责人(会计主 管人员)李强声明：保证季度报告中财务报表的真实、准确、完整。 1 吉林敖东药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | |-----------------------------------------------------------|-------------------|-------------------|------------------------- ...

Financial Performance - The company's operating revenue for 2020 was ¥2,251,650,950.38, a decrease of 27.09% compared to ¥3,088,379,591.97 in 2019[9] - The net profit attributable to shareholders for 2020 was ¥1,708,876,052.37, an increase of 21.75% from ¥1,403,640,313.56 in 2019[9] - The net profit after deducting non-recurring gains and losses was ¥1,647,506,111.99, up 28.97% from ¥1,277,462,446.54 in 2019[9] - The basic earnings per share for 2020 was ¥1.4753, representing a growth of 22.23% compared to ¥1.2070 in 2019[9] - The total assets at the end of 2020 were ¥27,353,457,083.87, an increase of 6.02% from ¥25,800,904,916.27 at the end of 2019[9] - The net assets attributable to shareholders at the end of 2020 were ¥23,353,020,520.01, a rise of 4.96% from ¥22,249,498,565.07 at the end of 2019[9] - The net cash flow from operating activities for 2020 was ¥390,408,759.72, an increase of 2.89% from ¥379,456,901.57 in 2019[9] - The diluted earnings per share for 2020 was ¥1.4298, which is a 20.92% increase from ¥1.1824 in 2019[9] - The weighted average return on equity for 2020 was 7.48%, up from 6.50% in 2019[9] Revenue Breakdown - In 2020, the company reported total revenue of approximately CNY 2.25 billion, with quarterly revenues of CNY 468.29 million, CNY 653.16 million, CNY 494.60 million, and CNY 635.61 million respectively[12] - The net profit attributable to shareholders for the year was approximately CNY 1.70 billion, with quarterly net profits of CNY 328.32 million, CNY 691.78 million, CNY 483.53 million, and CNY 205.25 million respectively[12] - The company's total assets at the end of 2020 were CNY 27.35 billion, and net assets were CNY 23.53 billion, maintaining a consistent profit tax exceeding CNY 1 billion for several years[15] - Pharmaceutical revenue accounted for CNY 1,905,975,932.48, representing 84.65% of total revenue, down 32.51% from CNY 2,823,902,969.94 in 2019[39] - The revenue from chain pharmacy wholesale and retail increased by 85.76% to CNY 141,502,333.68, compared to CNY 76,174,849.32 in 2019[39] Investment and R&D - Increased R&D investment to strengthen core capabilities and support high-quality development in the pharmaceutical industry[25] - New product development includes clinical research on Bai Lian Shen granules for lung cancer treatment and other traditional Chinese medicine formulations[26][27] - The company is pursuing a "dual-wheel drive" growth model combining industry and finance to support sustainable development[21] - The company is actively enhancing its industry layout and core competitiveness in the pharmaceutical sector through accelerated project construction[36] - The company is committed to enhancing its research capabilities across multiple areas, including clinical evidence-based medicine and quality improvement[28] Market Strategy and Expansion - The company is actively expanding into health food, agriculture, and other sectors, while continuing to develop its core pharmaceutical business[14] - The company is expanding its marketing strategy by integrating resources and enhancing product competitiveness based on consumer demand[31] - The company plans to focus on core traditional Chinese medicine products and adjust its product structure and channel coverage in response to national healthcare reforms and procurement policies[90] - The company aims to implement a sales policy of "leading varieties and multiple varieties progressing together" to enhance market competitiveness[86] Corporate Governance and Compliance - The company has maintained a good integrity status with no significant legal judgments or debts overdue during the reporting period[109] - The company has not faced any major litigation or arbitration matters during the reporting period[109] - The company has implemented strict insider information management to prevent leaks and ensure compliance with regulations[182] - The company has established an independent financial accounting department and management system, conducting financial decisions independently and maintaining separate bank accounts[185] Social Responsibility and Environmental Compliance - The company has a focus on social responsibility, integrating it into its strategic development[121] - The company has achieved compliance with environmental protection standards, with no exceedances reported during the reporting period[126] - The company has received environmental protection administrative permits for all its subsidiaries, adhering to local and national regulations[126] - The company has implemented various employee benefits to foster a learning organization and improve overall employee quality[38] Shareholder Returns - The company plans to distribute a cash dividend of ¥2 per 10 shares to all shareholders[2] - The total cash dividend (including other methods) for 2020 was 527,796,662.91 CNY, which accounted for 30.89% of the net profit attributable to shareholders[99] - The cash dividend policy was confirmed to comply with the company's articles of association and shareholder resolutions[96] - The company has not issued any bonus shares in the recent three years, maintaining a consistent cash dividend policy[98] Employee Engagement and Structure - The total number of employees in the company is 4,462, with 34 in the parent company and 4,428 in major subsidiaries[173] - The employee composition includes 1,938 production personnel, 1,414 sales personnel, 401 technical personnel, 141 financial personnel, and 568 administrative personnel[174] - The company has established a comprehensive training system to enhance employee skills and competitiveness[175] - The employee stock ownership plan is a significant part of the company's shareholding structure, indicating strong employee engagement[150]